Labeled for this condition
Medicines for overactive bladder
9 medicines have an FDA label indicated for overactive bladder; 7 are listed from generic labelers and 0 have a presentation in shortage now (FDA files, October 8, 2026).
Which medicines are labeled for overactive bladder?
Each label names the condition in its indications; the record shows the label's words. A list of labeled medicines is not a treatment plan.
| Medicine | Brand names | Generic labelers (all forms) | Pharmacy cost | Boxed warning | Shortage | Recalls since 2012 |
|---|---|---|---|---|---|---|
| Oxybutynin | Oxytrol | 39 labelers | $0.048 per tablet 5 mg tablet | No | No current entry | 9 |
| Solifenacin | none listed | 20 labelers | $0.162 per tablet 10 mg tablet | No | No current entry | 6 |
| Tolterodine | Detrol | 14 labelers | $0.268 per capsule 2 mg capsule | No | No current entry | 4 |
| Trospium | none listed | 19 labelers | $0.211 per tablet 20 mg tablet | No | No current entry | 1 |
| Fesoterodine | Toviaz | 11 labelers | $0.794 per tablet 4 mg tablet | No | No current entry | 2 |
| Mirabegron | Myrbetriq | 8 labelers | $9.39 per tablet 50 mg tablet | No | No current entry | 1 |
| Botulinum toxin type a | Xeomin, Botox, Dysport | none listed | n/a | Yes | No current entry | 0 |
| Darifenacin | none listed | 8 labelers | $0.432 per tablet 15 mg tablet | No | No current entry | 2 |
| Vibegron | Gemtesa | none listed | $16.46 per tablet 75 mg tablet | No | No current entry | 0 |
Source: FDA drug labels (indications) via openFDA; NDC Directory; CMS NADAC of October 7, 2026; FDA shortages and recalls (FDA files October 8, 2026)
What do pharmacies pay?
Each medicine's most widely listed form, per unit, in the NADAC survey: what pharmacies paid, not what a patient pays; strengths differ, so compare like with like.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price